Skip to main content
SpringerLink
Log in
Book cover

Continence pp 257–274Cite as

Botulinum Toxin: An Effective Treatment for Urge Incontinence

  • Chapter

  • 871 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Arnon SS, Schechter R, Inglesby TV,. et al. 2001; Botulinum toxin as a biological weapon: Medical and public health management. JAMA 285:(8)1059–1070.

    Article  PubMed  CAS  Google Scholar 

  2. Gill DM. 1982; Bacterial toxins: A table of lethal amounts. Microbiol Rev 46:(1)86–94.

    PubMed  CAS  Google Scholar 

  3. Simpson LL. 1986; Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 26:427–453.

    Article  PubMed  CAS  Google Scholar 

  4. Harper M, Fowler CJ, Dasgupta P. 2004; Botulinum toxin and its applications in the lower urinary tract. BJU Int 93:(6)702–706.

    Article  PubMed  CAS  Google Scholar 

  5. Angaut-Petit D, Molgo J, Comella JX,. et al. 1990; Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: Morphological and electrophysiological features. Neuroscience 37:(3)799–808.

    Article  PubMed  CAS  Google Scholar 

  6. Meunier FA, Schiavo G, Molgo J. 2002; Botulinum neurotoxins: From paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 96:(1–2)105–113.

    Article  PubMed  CAS  Google Scholar 

  7. de PA, Meunier FA, Molgo J,. et al. 1999; Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 96:(6)3200–3205.

    Article  Google Scholar 

  8. Naumann M, Jost WH, Toyka KV. 1999; Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol 56:(8)914–916.

    Article  PubMed  CAS  Google Scholar 

  9. de PA, Ashton AC, Foran P,. et al. 1993; Botulinum A like type B and tetanus toxins fulfils criteria for being a zinc-dependent protease. J Neurochem 61:(6)2338–2341.

    Article  Google Scholar 

  10. Schiavo G, Papini E, Genna G, Montecucco C. 1990; An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin. Infect Immun 58:(12)4136–4141.

    PubMed  CAS  Google Scholar 

  11. Herreros J, Lalli G, Montecucco G, Schiavo G. 2006.Pathophysiological properties of clostridial neurotoxins. In: The comprehensive sourcebook of bacterial protein toxins. , Academic PressLondon,

    Google Scholar 

  12. Schiavo G, Matteoli M, Montecucco C. 2000; Neurotoxins affecting neuroexocytosis. Physiol Rev 80:(2)717–766.

    PubMed  CAS  Google Scholar 

  13. Carpenter FG. 1967; Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rats. J Physiol 188:(1)1–11.

    PubMed  CAS  Google Scholar 

  14. Smith CP, Franks ME, McNeil BK,. et al. 2003; Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169:(5)1896–1900.

    Article  PubMed  CAS  Google Scholar 

  15. Burnstock G. 1972; Purinergic nerves. Pharmacol Rev 24:(3)509–581.

    PubMed  CAS  Google Scholar 

  16. Mackenzie I, Burnstock G, Dolly JO. 1982; The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7:(4)997–1006.

    Article  PubMed  CAS  Google Scholar 

  17. Bayliss M, Wu C, Newgreen D,. et al. 1999; A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol 162:(5)1833–1839.

    Article  PubMed  CAS  Google Scholar 

  18. O’Reilly BA, Kosaka AH, Knight GF,. et al. 2002; P2X receptors and their role in female idiopathic detrusor instability. J Urol 167:(1)157–164.

    Article  PubMed  Google Scholar 

  19. Mackenzie I, Burnstock G, Dolly JO. 1982; The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7:(4)997–1006.

    Article  PubMed  CAS  Google Scholar 

  20. Smith CP, Franks ME, McNeil BK,. et al. 2003; Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169:(5)1896–1900.

    Article  PubMed  CAS  Google Scholar 

  21. Mackenzie I, Burnstock G, Dolly JO. 1982; The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7:(4)997–1006.

    Article  PubMed  CAS  Google Scholar 

  22. Smith CP, Franks ME, McNeil BK,. et al. 2003; Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169:(5)1896–1900.

    Article  PubMed  CAS  Google Scholar 

  23. Apostolidis A, Dasgupta P, Fowler CJ. 2006; Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:(4)644–650.

    Article  PubMed  CAS  Google Scholar 

  24. Smet PJ, Moore KH, Jonavicius J. 1997; Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 77:(1)37–49.

    PubMed  CAS  Google Scholar 

  25. Khera M, Somogyi GT, Kiss S,. et al. 2004; Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury. Neurochem Int 45:(7)987–993.

    Article  PubMed  CAS  Google Scholar 

  26. Rapp DE, Turk KW, Bales GT, Cook SP. 2006; Botulinum toxin type A inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175:(3 Pt 1)1138–1142.

    Article  PubMed  CAS  Google Scholar 

  27. Chuang YC, Yoshimura N, Huang CC,. et al. 2004; Intravesical botulinum toxin A administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172:(4 Pt 1)1529–1532.

    Article  PubMed  CAS  Google Scholar 

  28. Atiemo H, Wynes J, Chuo J,. et al. 2005; Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 65:(3)622–626.

    Article  PubMed  Google Scholar 

  29. Apostolidis A, Dasgupta P, Fowler CJ. 2006; Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:(4)644–650.

    Article  PubMed  CAS  Google Scholar 

  30. Apostolidis A, Popat R, Yiangou Y,. et al. 2005; Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174:(3)977–982.

    Article  PubMed  CAS  Google Scholar 

  31. Welch MJ, Purkiss JR, Foster KA. 2000; Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins Toxicon 38:(2)245–258.

    Article  PubMed  CAS  Google Scholar 

  32. Purkiss JR, Welch MJ, Doward S,. et al. 1998; A method for the measurement of [3H]-glutamate release from cultured dorsal root ganglion neurons. Biochem Soc Trans 26:(2)S108.

    PubMed  CAS  Google Scholar 

  33. Cui M, Khanijou S, Rubino J, Aoki KR. 2004; Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:(1–2)125–133.

    Article  PubMed  CAS  Google Scholar 

  34. Aoki KR. 2005; Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26:(5)785–793.

    Article  PubMed  CAS  Google Scholar 

  35. Jankovic J, Schwartz K. 1990; Botulinum toxin injections for cervical dystonia. Neurology 40:(2)277–280.

    PubMed  CAS  Google Scholar 

  36. Leippold T, Reitz A, Schurch B. 2003; Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur Urol 44:(2)165–174.

    Article  PubMed  CAS  Google Scholar 

  37. Smith CP, Chancellor MB. 2004; Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 171:(6 Pt 1)2128–2137.

    Article  PubMed  CAS  Google Scholar 

  38. Sahai A, Khan M, Fowler CJ, Dasgupta P. 2005; Botulinum toxin for the treatment of lower urinary tract symptoms: A review. Neurourol Urodyn 24:(1)2–12.

    Article  PubMed  CAS  Google Scholar 

  39. Schurch B, Stohrer M, Kramer G,. et al. 2000; Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164:(3 Pt 1)692–697.

    PubMed  CAS  Google Scholar 

  40. Kessler TM, Danuser H, Schumacher M, et al. 2005; Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24:(3)231–236.

    Article  PubMed  CAS  Google Scholar 

  41. Bagi P, Biering-Sorensen F. 2004; Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38:(6)495–498.

    Article  PubMed  CAS  Google Scholar 

  42. Hajebrahimi S, Altaweel W, Cadoret J,. et al. 2005; Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: Initial results. Can J Urol 12:(1)2543–2546.

    PubMed  CAS  Google Scholar 

  43. Schulte-Baukloh H, Schobert J, Stolze T,. et al. 2006; Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: An objective and subjective analysis. Neurourol Urodyn 25:(2)110–115.

    Article  PubMed  CAS  Google Scholar 

  44. Klaphajone J, Kitisomprayoonkul W, Sriplakit S. 2005; Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 86:(11)2114–2118.

    Article  PubMed  Google Scholar 

  45. Reitz A, Stohrer M, Kramer G,. et al. 2004; European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:(4)510–515.

    Article  PubMed  CAS  Google Scholar 

  46. Kuo HC. 2006; Therapeutic effects of suburothelial injection of botulinum A toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology 67:(2)232–236.

    Article  PubMed  Google Scholar 

  47. Grosse J, Kramer G, Stohrer M. 2005; Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:(5)653–659.

    Article  PubMed  CAS  Google Scholar 

  48. Patki PS, Hamid R, Arumugam K,. et al. 2006; Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 98:(1)77–82.

    Article  PubMed  CAS  Google Scholar 

  49. Ruffion A, Capelle O, Paparel P,. et al. 2006; What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97:(5)1030–1034.

    Article  PubMed  CAS  Google Scholar 

  50. Schurch B, de SM, Denys P,. et al. 2005; Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:(1)196–200.

    Article  PubMed  CAS  Google Scholar 

  51. Szallasi A, Blumberg PM. 1996; Vanilloid receptors: New insights enhance potential as a therapeutic target. Pain 68:(2–3)195–208.

    Article  PubMed  CAS  Google Scholar 

  52. Chancellor MB, de Groat WC. 1999; Intravesical capsaicin and resiniferatoxin therapy: Spicing up the ways to treat the overactive bladder. J Urol 162:(1)3–11.

    Article  PubMed  CAS  Google Scholar 

  53. Fowler CJ, Jewkes D, McDonald WI,. et al. 1992; Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 339:(8803)1239.

    Article  PubMed  CAS  Google Scholar 

  54. Giannantoni A, Di Stasi SM, Stephen RL,. et al. 2004; Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: A prospective randomized study. J Urol 172:(1)240–243.

    Article  PubMed  CAS  Google Scholar 

  55. Rapp DE, Lucioni A, Katz EE,. et al. 2004; Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: An initial experience. Urology 63:(6)1071–1075.

    Article  PubMed  Google Scholar 

  56. Smith CP, Nishiguchi J, O'Leary M,. et al. 2005; Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 65:(1)37–41.

    Article  PubMed  Google Scholar 

  57. Kuo HC. 2005; Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66:(1)94–98.

    Article  PubMed  Google Scholar 

  58. Werner M, Schmid DM, Schussler B. 2005; Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: A prospective nonrandomized study. Am J Obstet Gynecol 192:(5)1735–1740.

    Article  PubMed  CAS  Google Scholar 

  59. Flynn MK, Webster GD, Amundsen CL. 2004; The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 172:(6 Pt 1)2316–2320.

    Article  PubMed  CAS  Google Scholar 

  60. Kuo HC. 2004; Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:(5)868–872.

    Article  PubMed  Google Scholar 

  61. Popat R, Apostolidis A, Kalsi V,. et al. 2005; A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174:(3)984–989.

    Article  PubMed  CAS  Google Scholar 

  62. Kalsi V, Apostolidis A, Popat R,. et al. 2006; Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:(3)528–535.

    Article  PubMed  Google Scholar 

  63. Schulte-Baukloh H, Weiss C, Stolze T,. et al. 2005; Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: Objective outcome and patient satisfaction. Eur Urol 48:(6)984–990.

    Article  PubMed  Google Scholar 

  64. Schmid DM, Sauermann P, Werner M,. et al. 2006; Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176:(1)177–185.

    Article  PubMed  CAS  Google Scholar 

  65. Sahai A, Khan MS, Dasgupta P. 2007; Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: Results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177:(6)2231–2236.

    Article  PubMed  CAS  Google Scholar 

  66. Schulte-Baukloh H, Michael T, Schobert J,. et al. 2002; Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: Preliminary results. Urology 59:(3)325–327.

    Article  PubMed  CAS  Google Scholar 

  67. Riccabona M, Koen M, Schindler M,. et al. 2004; Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171:(2 Pt 1)845–848.

    Article  PubMed  CAS  Google Scholar 

  68. Altaweel W, Jednack R, Bilodeau C, Corcos J. 2006; Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 175:(3 Pt 1)1102–1105.

    Article  PubMed  CAS  Google Scholar 

  69. Hoebeke P, De CK, Vande WJ,. et al. 2006; The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 176:(1)328–330.

    Article  PubMed  CAS  Google Scholar 

  70. Schulte-Baukloh H, Knispel HH, Stolze T,. et al. 2005; Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 66:(4)865–870.

    Article  PubMed  Google Scholar 

  71. Dykstra DD, Pryor J, Goldish G. 2003; Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: A case report. Arch Phys Med Rehabil 84:(9)1399–1400.

    Article  PubMed  Google Scholar 

  72. Dykstra D, Enriquez A, Valley M. 2003; Treatment of overactive bladder with botulinum toxin type B: A pilot study. Int Urogynecol J Pelvic Floor Dysfunct 14:(6)424–426.

    Article  PubMed  Google Scholar 

  73. Pistolesi D, Selli C, Rossi B, Stampacchia G. 2004; Botulinum toxin type B for type A resistant bladder spasticity. J Urol 171:(2 Pt 1)802–803.

    Article  PubMed  CAS  Google Scholar 

  74. Reitz A, Schurch B. 2004; Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 171:(2 Pt 1)804–805.

    Article  PubMed  Google Scholar 

  75. Ghei M, Maraj BH, Miller R,. et al. 2005; Effects of botulinum toxin B on refractory detrusor overactivity: A randomized, double-blind, placebo controlled, crossover trial. J Urol 174:(5)1873–1877.

    Article  PubMed  CAS  Google Scholar 

  76. Apostolidis A, Dasgupta P, Fowler CJ. 2006; Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49:(4)644–650.

    Article  PubMed  CAS  Google Scholar 

  77. Harper M, Popat RB, Dasgupta R,. et al. 2003; A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92:(3)325–326.

    Article  PubMed  CAS  Google Scholar 

  78. Sahai A, Kalsi V, Khan MS, Fowler CJ. 2006; Techniques for the intradetrusor administration of botulinum toxin. BJU Int 97:(4)675–678.

    Article  PubMed  Google Scholar 

  79. Smith CP, Chancellor MB. 2005; Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 19:(7)880–882.

    Article  PubMed  Google Scholar 

  80. Schulte-Baukloh H, Knispel HH. 2005; A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 95:(3)454.

    Article  PubMed  Google Scholar 

  81. Scott AB, Suzuki D. 1988; Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3:(4)333–335.

    Article  PubMed  CAS  Google Scholar 

  82. Wyndaele JJ, Van Dromme SA. 2002; Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40:(11)599–600.

    Article  PubMed  CAS  Google Scholar 

  83. Santos JI, Swensen P, Glasgow LA. 1981; Potentiation of Clostridium botulinum. toxin aminoglycoside antibiotics: Clinical and laboratory observations Pediatrics 68:(1)50–54.

    PubMed  CAS  Google Scholar 

  84. Pellizzari R, Rossetto O, Schiavo G, Montecucco C. 1999; Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 354:(1381)259–268.

    Article  PubMed  CAS  Google Scholar 

  85. Eleopra R, Tugnoli V, Rossetto O,. et al. 1997; Botulinum neurotoxin serotype C: A novel effective botulinum toxin therapy in human. Neurosci Lett 224:(2)91–94.

    Article  PubMed  CAS  Google Scholar 

  86. Meunier FA, Schiavo G, Molgo J. 2002; Botulinum neurotoxins: From paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 96:(1–2)105–113.

    Article  PubMed  CAS  Google Scholar 

  87. Smith CP, Boone TB, de Groat WC,. et al. 2003; Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull 61:(2)165–171.

    Article  PubMed  CAS  Google Scholar 

  88. Comperat E, Reitz A, Delcourt A,. et al. 2006; Histologic features in the urinary bladder wall affected from neurogenic overactivity – a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol 50:1058–1064.

    Article  PubMed  CAS  Google Scholar 

  89. Haferkamp A, Schurch B, Reitz A,. et al. 2004; Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 46:(6)784–791.

    Article  PubMed  CAS  Google Scholar 

  90. Haferkamp A, Schurch B, Reitz A,. et al. 2004; Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 46:(6)784–791.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, St. Guy’s Hospital, London, UK

    Arun Sahai & Prokar Dasgupta

Authors
  1. Arun Sahai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Shamim Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prokar Dasgupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Wake Forest University Baptist Medical Center, Winston Salem, NC, USA

    Gopal H. Badlani MD

  2. Department of Gynecology, Cleveland Clinic Florida, Weston, FL, USA

    G. Willy Davila MD

  3. Department of Pharmacology and Pharmacotherapy Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    Martin C. Michel MD, MAE

  4. Department of Urology Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

    Jean J. M. C. H. de la Rosette MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London Limited

About this chapter

Cite this chapter

Sahai, A., Khan, M.S., Dasgupta, P. (2009). Botulinum Toxin: An Effective Treatment for Urge Incontinence. In: Badlani, G.H., Davila, G.W., Michel, M.C., de la Rosette, J.J.M.C.H. (eds) Continence. Springer, London. https://doi.org/10.1007/978-1-84628-510-3_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-510-3_20

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-510-3

  • Online ISBN: 978-1-84628-734-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation